Call Us + 33 1 84 88 31 00

Article R1124-3 of the French Public Health Code

Notwithstanding the first paragraph of Article R. 1124-2, the following shall be allocated to the Committee for the Protection of Individuals to which the matter has previously been referred:

1° Clinical trial assessment application dossiers that have, in the Union portal mentioned in Article 80 of the aforementioned Regulation of 16 April 2014, the same EU trial number as a previous dossier that has lapsed, been withdrawn or that has not been validated under the conditions provided for in Article 5 of this Regulation;

2° Dossiers that are the subject of a new submission under the conditions provided for in Article 13 of the aforementioned Regulation;

3° Applications for substantial amendments to the initial clinical trial.

Original in French 🇫🇷
Article R1124-3

Par dérogation au premier alinéa de l’article R. 1124-2, sont attribués au comité de protection des personnes préalablement saisi :


1° Les dossiers de demande d’évaluation d’un essai clinique disposant, dans le portail de l’Union mentionné à l’article 80 du règlement du 16 avril 2014 susmentionné, du même numéro UE d’essai qu’un précédent dossier devenu caduc, retiré ou qui n’a pas été validé dans les conditions prévues à l’article 5 de ce règlement ;


2° Les dossiers faisant l’objet d’un nouveau dépôt dans les conditions prévues à l’article 13 du règlement susmentionné ;


3° Les dossiers de demande de modifications substantielles de l’essai clinique initial.

Need help with this article? Get help from a French lawyer

Our French business lawyers are here to help.
We offer a FREE evaluation of your case.
Call us at +33 (0) 1 84 88 31 00 or send us an email.

Useful links

You have a question in French Business Law?

Our French business lawyers are here to help.
We offer a FREE evaluation of your case.
Call +33 (0) 1 84 88 31 00 or send us an email.

All information exchanged through this website will be communicated to lawyers registered with a French Bar and will remain confidential.